Search

Your search keyword '"VASCULAR endothelial growth factor antagonists"' showing total 520 results

Search Constraints

Start Over You searched for: Descriptor "VASCULAR endothelial growth factor antagonists" Remove constraint Descriptor: "VASCULAR endothelial growth factor antagonists" Topic diabetic retinopathy Remove constraint Topic: diabetic retinopathy
520 results on '"VASCULAR endothelial growth factor antagonists"'

Search Results

1. Is there a relationship between the first-day results of anti-VEGF therapy for macular edema due to vascular diseases and longterm outcomes?

2. Diyabetik Retinopatide Maküla ve Peripapiller Retinanın Değerlendirilmesinde Heidelberg Retinal Tomografi III Cihazı Retina Modülünün Kullanımı.

3. Health-related quality of life in patients with neovascular age-related macular degeneration: a prospective cohort study.

4. Emergent therapeutics for the treatment of diabetic macular edema.

5. Comparing the efficacy of dexamethasone implant and anti-VEGF for the treatment of macular edema: A systematic review and meta-analysis.

6. Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy.

7. Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review.

8. Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice.

9. Impact of intravitreal anti-VEGF therapy on intraretinal microvascular abnormalities in proliferative diabetic retinopathy.

10. Sodium‐glucose co‐transporter 2 inhibitor therapy reduces the administration frequency of anti‐vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti‐vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database

11. Role of Intravitreal Dexamethasone Implant in the Management of Treatment-Naive Diabetic Macular Edema: A Pre-Cataract Surgical Approach for Patients with Systemic Contraindications to Anti-VEGF Therapy.

12. Biosimilars for Retinal Diseases: A Review of the Literature.

13. Management of Nonproliferative Diabetic Retinopathy: Where Do We Stand?

14. Regression of Neovascularization after Panretinal Photocoagulation Combined with Anti-VEGF Injection for Proliferative Diabetic Retinopathy—A Review.

15. Exploring the therapeutic possibilities of TNF inhibitors in retinal diseases: How TNF inhibitors may enhance retina treatment both alone and in combination with other drugs.

16. Correlation between Topographic Vessel Density and Retinal Thickness Changes in Patients with Diabetic Macular Edema Treated with Anti-VEGF Therapy: Is It a Suitable OCTA Biomarker?

17. Long-Term Change in Renal Function After Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema: A 2-Year Retrospective Cohort Study.

18. Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema.

19. Early effects of intravitreal anti-VEGF agents on cornea and visual acuity in patients with diabetic retinopathy.

20. Comparison of Dexamethasone Implant and Anti-VEGF Agents in the Treatment of Naive Diabetic Macular Oedema: A Prospective Cohort Study Patients on Stabilised Doses of Psychotropics during Coronavirus Infection: A Case Series.

21. Comparison of micropulse subthreshold laser plus anti-VEGF versus anti-VEGF alone in diabetic macular edema: Systematic review.

22. The Long-Term Observation of the Beneficial Effects of Treatment: 0.12 mg Anti-VEGF Monotherapy or Anti-VEGF Combined Therapy and Diode-Laser in Various Stages of Retinopathy of Prematurity—Series of Cases.

23. Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice.

24. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.

25. Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice.

26. Appropriate timing schedule for intravitreal anti-VEGF injection as adjuvant therapy before pars-plana vitrectomy in proliferative diabetic retinopathy, a meta analysis.

27. A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment.

28. Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy.

29. Bone Morphogenetic Protein-4 Impairs Retinal Endothelial Cell Barrier, a Potential Role in Diabetic Retinopathy.

30. Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023.

31. Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries.

32. Associations and Prognostic Significance of Fluctuations in Diabetic Retinopathy Severity in Eyes Treated for Diabetic Macular Edema.

33. Fisetin Prevents Angiogenesis in Diabetic Retinopathy by Downregulating VEGF.

34. Reduced Size of Telangiectatic Capillaries After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents in Diabetic Macular Edema.

35. The Effects of Re-vitrectomy and Intravitreal anti-VEGF Treatments on Visual Outcome in Diabetic Vitreous Hemorrhage After Pars Plana Vitrectomy.

36. A Survey of the Management of Diabetic Macular Oedema in Sub-Saharan Africa.

37. Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience.

38. Determinants of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment Outcomes in Diabetic Patients Having Macular Edema.

39. The long-term impact of anti-VEGF therapy for DME: A review of real-world evidence that examines the extended effectiveness of treatment.

40. Understanding the risk of GA in nAMD: A look at research that sheds new light into the progression of geographic atrophy in neovascular age-related macular degeneration.

41. 4D-150 reduces annualized anti-VEGF injection rate in wet AMD at 24 weeks.

42. Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema.

43. Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy.

44. Endocannabinoids and related compounds as modulators of angiogenesis: Concepts and clinical significance.

45. VABYSMO® (faricimab-svoa) the First Dual Pathway Inhibitor.

46. Progress of Diabetic Macular Edema after Loading Injection of Anti-Vascular Endothelial Growth Factor Agents in Real-World Cases.

47. Long term outcomes following anti-VEGF therapy for diabetic macular edema.

48. Researchers Submit Patent Application, "Use Of Alpha-Enolase Antagonist For Treating Angiogenesis-Related Diseases", for Approval (USPTO 20250034278).

49. Medical University of Warsaw Researchers Publish New Study Findings on Diabetic Retinopathy (The Silent Threat: Understanding and Managing Diabetic Retinopathy).

50. 3 Things You Should Know About nAMD and DME Treatment Updates.

Catalog

Books, media, physical & digital resources